A WORLD WITHOUT CANCER: WE’RE BRINGING IT CLOSER EVERY DAY

Despite all the advances the oncology community has seen since 1987 when we came to America, there are still too many cancer patients with unmet needs. That’s why, as a human health care company, we keep increasing our commitment to oncology. We won’t stop pursuing breakthroughs until the world is cancer-free. Please visit our clinical trials area for information about open Eisai oncology studies.

LEARN THE LATEST ON HOW WE’RE HELPING PEOPLE LIVING WITH CANCER

MISSION ACCEPTED: THE NEXT EVOLUTION OF IMMUNO-ONCOLOGY (I-O)

To date, “immuno-oncology” has been synonymous with one modality. Eisai’s aim is to show that other modalities — alone, in combination or in sequence with checkpoint inhibitors — may help to normalize or even enhance the immune microenvironment and enhance antitumor activity. This is what our pipeline has been designed to explore.

The same small molecule and translational medicine expertise that served as the foundation for Eisai Oncology's current portfolio is also powering the future of our oncology pipeline. Combined with our Big Data, human biology and cancer genomics capabilities, we are poised to expand immuno-oncology as we know it to usher in a new era of personalized cancer medicines.

OUR PIPELINE LEADS STRAIGHT TO THE FUTURE OF ONCOLOGY

We’re pursuing potential breakthroughs designed to:

  • Modulate the microenvironment of a broad range of tumors
  • Inhibit signaling pathways that play important roles to inactivate the immune system
  • Leverage cancer genomics to target cancer drivers, tumor resistance and immune evasion